
Jocelyn Ulrich Jocelyn Ulrich, MPH, is Deputy Vice President, Policy and Research, at the Pharmaceutical Research and Manufacturers of America (PhRMA). At PhRMA, she is responsible for developing legislative and policy analysis and research studies on a range of issues impacting innovative biopharmaceutical companies including intellectual property issues, FDA policy issues, the R&D process, the value of innovation, and other issue areas impacting the environment for innovation. In addition to her experience at PhRMA she has over 15 years of experience in the pharmaceutical industry at Pfizer, Human Genome Sciences, and EMD Serono in roles in clinical research management, investigator-initiated and collaborative research, and global policy and corporate affairs. Jocelyn holds an MPH in global health policy and management from New York University.
Recent Posts
Policies need to address the growing threat of antimicrobial resistance

Protecting treatment advances for breast cancer

Don’t take anti-innovation, activist funded academics at their word

Biosimilar uptake is increasing and so are health savings

Research and development continues long after a medicine is initially approved

ICYMI: New report demonstrates growing global impact of antimicrobial resistance

Preventing the next public health emergency: New evidence demonstrates need to address antimicrobial resistance

ICYMI: Report provides actionable recommendations to strengthen America’s preparedness and future health crises response

The next threat: Combatting antimicrobial resistance

New Graphic: Public-Private collaboration fuels the U.S. biopharmaceutical ecosystem
